Coltuximab Ravtansine

Preferred Label : Coltuximab Ravtansine;

NCIt synonyms : Anti-CD19-DM4 Conjugate; Anti-CD19-DM4 Immunoconjugate SAR3419;

NCIt definition : An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Coltuximab ravtansine targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.;

UNII : MRS84YT9L2;

CAS number : 1269764-99-9;

Molecule name : SAR-3419; SAR 3419;

Codes from synonyms : 114;

Details

Origin ID

C71009;

UMLS CUI

C4508929;

CISMeF manual mappings
- coltuximab ravtansine [MeSH concept]
Currated CISMeF NLP mapping
- coltuximab ravtansine [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- SAR 3419 [MeSH concept]
- coltuximab ravtansine [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients